Patents by Inventor Peter Tai Wah Cheng

Peter Tai Wah Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210379210
    Abstract: The present invention relates to radiolabeled LPA1 receptor antagonists of Formula (I) or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein, which are useful for the quantitative imaging of LPA1 receptors in mammals.
    Type: Application
    Filed: October 14, 2019
    Publication date: December 9, 2021
    Inventors: Peter Tai Wah Cheng, James R. Corte, David J. Donnelly, Joonyoung Kim, Jun Shi, Shiwei Tao, Tritin Tran
  • Patent number: 11180488
    Abstract: The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; L is C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyallcyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 is hydrogen, C1-6 alkyl, C1-6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy, and the alkyl, by itself or as part of other moiety, is optionally substituted with deuterium partially or fully; R4 is C1-10 alkyl, C1-10 deuterated alkyl, C1-10 haloalkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, —(C1-6 alkylene)-(C3-8 cycl
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 23, 2021
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Hao Zhang, Yan Shi, Jun Li
  • Publication number: 20210317131
    Abstract: The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: September 16, 2019
    Publication date: October 14, 2021
    Inventors: Peter Tai Wah Cheng, Jun Shi, Shiwei Tao, Hao Zhang
  • Publication number: 20210244711
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: April 5, 2021
    Publication date: August 12, 2021
    Inventors: PETER TAI WAH CHENG, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Publication number: 20210230143
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: July 29, 2021
    Inventors: Yan Shi, Ying Wang, Peter Tai Wah Cheng, Jun Shi, Shiwei Tao, James R. Corte, Tianan Fang, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Sutjano Jusuf
  • Publication number: 20210163470
    Abstract: The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: June 3, 2021
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Li, Tianan Fang, James R. Corte, Jun Shi, Hao Zhang, Lawrence J. Kennedy, Shiwei Tao
  • Patent number: 11008300
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • Patent number: 11007180
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Publication number: 20210087178
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: March 25, 2021
    Inventors: Yan Shi, Ying Wang, Peter Tai Wah Cheng, Jun Li, Steven J. Walker
  • Publication number: 20210087173
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; Q2 is N or NR5a; one of Q1 and Q3 is CR5, and the other is N or NR5a; and the dashed circle denotes optional bonds forming an aromatic ring; Y1 is O or NR3; Y2 is —CO—, —SO2—, or —S(O(NH)—; Y3 is O or NR4a; provided that (1) Y1 and Y3 are not both O, and (2) when Y2 is C(O), Y1 is not O; L is a covalent bond or C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 and R4a are independently hydrogen, C1-6 alkyl, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or
    Type: Application
    Filed: December 18, 2018
    Publication date: March 25, 2021
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang
  • Publication number: 20210078982
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: March 18, 2021
    Inventors: Yan Shi, Peter Tai Wah Cheng, Hao Zhang, Jun Li, Tianan Fang, James R. Corte
  • Publication number: 20200317656
    Abstract: The present invention provides compounds of Formula (Ia) or (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: October 8, 2020
    Inventors: YAN SHI, Ying Wang, Peter Tai Wah Cheng
  • Publication number: 20200317662
    Abstract: The present invention provides compounds of Formula (Ia) or (Ib):Formula (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: October 8, 2020
    Inventors: Peter Tai Wah Cheng, Yan Shi, Hao Zhang
  • Publication number: 20200317655
    Abstract: The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein wherein X1, X2, X3, and X4 are each independently CR6 or N; provided that no more than two of X1, X2, X3, or X4 are N; L is C1-4 alkylene substituted with 0 to 4 R7; R1 is (—CH2)aR9; a is an integer of 0 or 1; R2 is each independently halo, cyano, hydroxyl, amino, C1-6 alkyl, C3-6 cycloalkyl, C4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkoxyallcyl, or haloalkoxy; n is an integer of 0, 1, or 2; R3 is hydrogen, C1-6 alkyl, C1-6 deuterated alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy, and the alkyl, by itself or as part of other moiety, is optionally substituted with deuterium partially or fully; R4 is C1-10 alkyl, C1-10 deuterated alkyl, C1-10 haloalkyl, C1-10 alkenyl, C3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, —(C1-6 alkylene)-(C
    Type: Application
    Filed: December 18, 2018
    Publication date: October 8, 2020
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach lll, Hao Zhang, Yan Shi, Jun Li
  • Publication number: 20200308148
    Abstract: The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: October 1, 2020
    Inventors: Peter Tai Wah Cheng, Jun Li, Yan Shi, Ying Wang, Hao Zhang, Lawrence J. Kennedy, Steven J. Walker, Ramesh Babu Reddigunta
  • Publication number: 20200308157
    Abstract: The present invention provides compounds of Formula (Ia) and (Ib): (Ia) or (Ib), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: December 18, 2018
    Publication date: October 1, 2020
    Inventors: Peter Tai Wah CHENG, Yan SHI, Robert F. KALTENBACH, III, Ying WANG, Hao ZHANG
  • Patent number: 10662172
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 26, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • Publication number: 20200148665
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: January 16, 2020
    Publication date: May 14, 2020
    Inventors: Yan Shi, Peter Tai Wah Cheng, Ying Wang, Jun Shi, Shiwei Tao, Jun Li, Lawrence J. Kennedy, Robert F. Kaltenbach, III, Hao Zhang, James R. Corte
  • Publication number: 20200138789
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Application
    Filed: January 2, 2020
    Publication date: May 7, 2020
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • Patent number: 10604541
    Abstract: A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 31, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Wei Meng, Mark Liu, Bei Wang, Rulin Zhao